Merck KGaA (FRA:MRK) received a €100.00 ($116.28) target price from stock analysts at Oddo Bhf in a research report issued to clients and investors on Wednesday. The brokerage currently has a “neutral” rating on the healthcare company’s stock. Oddo Bhf’s target price indicates a potential upside of 4.19% from the stock’s current price.
MRK has been the subject of a number of other research reports. Barclays set a €70.00 ($81.40) price objective on shares of Merck KGaA and gave the company a “sell” rating in a report on Friday, August 24th. Sanford C. Bernstein set a €105.00 ($122.09) price objective on shares of Merck KGaA and gave the company a “buy” rating in a report on Tuesday. Berenberg Bank set a €102.00 ($118.60) price target on shares of Merck KGaA and gave the company a “buy” rating in a report on Thursday, August 30th. Goldman Sachs Group set a €92.00 ($106.98) price target on shares of Merck KGaA and gave the company a “neutral” rating in a report on Wednesday, September 12th. Finally, Societe Generale set a €92.00 ($106.98) price target on shares of Merck KGaA and gave the company a “neutral” rating in a report on Friday, August 10th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of €98.00 ($113.95).
Shares of MRK opened at €95.98 ($111.60) on Wednesday. Merck KGaA has a 1-year low of €76.60 ($89.07) and a 1-year high of €115.00 ($133.72).
MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Featured Article: Institutional Investors
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.